Throughout Donald Trump’s presidency, the Republican White House embraced the “Friday night news dump” with unnerving enthusiasm. If it was a Friday night ahead of a holiday weekend, the public was even more likely to see — or if the strategy was executed effectively, not see — a provocative announcement.
As we were reminded late last week, Trump-appointed judges occasionally make use of the same tactics. NBC News reported on an important ruling that was issued late on Good Friday, during Passover, ahead of a holiday weekend.
In an unprecedented move, U.S. District Judge Matthew Kacsmaryk on Friday suspended the Food and Drug Administration’s longtime approval of key abortion pill mifepristone, though he gave the government a week to appeal his decision. If the ruling does eventually go into effect, it would curtail access to the standard regimen for medication abortion nationwide.
As a Slate analysis added, the judge’s order marked “the first time in history that a court has claimed the authority to single-handedly pull a drug from the market, a power that courts do not, in fact, have.”
For those unfamiliar with mifepristone, the FDA approved it nearly a quarter of a century ago, be used as part of a two-step process to terminate unwanted pregnancies up to 10 weeks. The drug has proven to be safe, effective and commonly used.
And according to a Trump-appointed judge in Texas, access to this safe, effective and commonly used medication must be curtailed across the country.
After Republican-appointed justices on the U.S. Supreme Court overturned Roe v. Wade, one of the more frequently used talking points on the right was that the fight over reproductive rights would now simply be a state-by-state issue. The demise of the Roe precedent wouldn’t impose a new national policy, conservatives said, because states that support abortion rights could continue to implement progressive policies.
Kacsmaryk’s ruling was a timely reminder that this talking point was, and is, a sham.
As the legal and political worlds absorbed Friday night’s developments, the broader legal landscape is admittedly complex. As MSNBC colleague Jordan Rubin explained, the ruling out of Texas roughly coincided with the release of a rival ruling from a district court in the state of Washington, which came to the opposite conclusion. That ruling ordered the FDA not to alter the availability of mifepristone, though it applies only to the states involved in this specific litigation, and not the whole country.
The next step will be a series of appeals, and it’s increasingly easy to believe that with competing decisions in competing courts, the matter will need to be resolved by the U.S. Supreme Court — filled with the same justices who overturned Roe less than a year ago.
The stakes are dramatic, not only because of abortion, but also, as The New York Times reported, Kacsmaryk’s ruling “poses threats to the U.S. government’s regulatory authority that could go far beyond one drug.”
But as the process plays out, it’s worth pausing to reflect on the scourge of a corrupt judicial system.
I’m not referring to graft or bribery, but rather an ideological corruption that weakens the judiciary and the public’s capacity to have faith in the integrity of the courts.








